- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Zydus Lifesciences Limited — Updates, 06-02-2026: Press Release
06-02-2026 | 12:18 pm
06-02-2026 | 12:18 pm
Zydus secured USFDA Orphan Drug status for Desidustat in Sickle Cell Disease. This pivotal designation offers potential 7-year market exclusivity post-approval, setting the stage for significant long-term value and addressing a critical unmet medical need.
No comments yet. Be the first to comment!